09Jan/14

Seattle Gentics-AbbVie Deal Expanded – Zacks.com

Antibodies

Drug Discovery & Development

Seattle Gentics-AbbVie Deal Expanded
Zacks.com
AbbVie will pay an upfront fee of $25 million for additional rights of using Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets. Seattle Genetics could receive up to $255 million from AbbVie in the form of potential …
Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with …Wall Street Journal
Seattle Genetics and AbbVie Broaden Cancer PartnershipMotley Fool
Seattle Genetics and AbbVie Broaden PartnershipPharmaceutical Processing

all 20 news articles »
09Jan/14

CLL Trial Stopped as Ibrutinib Shows Significant Benefits – Medscape

Monoclonal Anti-CD20 Antibodies

Medscape

CLL Trial Stopped as Ibrutinib Shows Significant Benefits
Medscape
The only agent so far to have shown an early definitive overall survival benefit in CLL is rituximab (Rituxan, Genentech/Roche), and hence a combination of ibrutinib with rituximab is very appealing — and trials of this combination are in progress …
J&J’s Imbruvica tops Arzerra in phase III trialPMLiVE

all 52 news articles »
09Jan/14

Anti-CD20 Antibody + Chemo Benefits CLL With Comorbidity – Monthly Prescribing Reference

Monoclonal Anti-CD20 Antibodies

HealthDay

Anti-CD20 Antibody + Chemo Benefits CLL With Comorbidity
Monthly Prescribing Reference
(HealthDay News) – For patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to …
New Drug Combo Might Help Older, Sicker Patients With LeukemiaHealthDay

all 6 news articles »
09Jan/14

Was hat sich 2013 in der MS-Therapie getan? – AMSEL – Multiple Sklerose … – Multiple Sklerose News: Startseite

Monoclonal Anti-IL-2Rα Receptor Antibodies

Was hat sich 2013 in der MS-Therapie getan? – AMSEL – Multiple Sklerose …
Multiple Sklerose News: Startseite
In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko …

and more »
09Jan/14

Was hat sich 2013 in der MS-Therapie getan? – Multiple Sklerose News: Startseite

Monoclonal Anti-IL-2Rα Receptor Antibodies

Multiple Sklerose News: Startseite

Was hat sich 2013 in der MS-Therapie getan?
Multiple Sklerose News: Startseite
In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko …

and more »